4-[2]thienyl-butyric acid amide | 4653-12-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-[2]thienyl-butyric acid amide
• 英文别名: 4-[2]Thienyl-buttersaeure-amid；4-(2-thienyl)-butylamide；4-(thien-2-yl)butanamide；4-<2>Thienyl-butyramid；4-(2-Thienyl)butanamide；4-thiophen-2-ylbutanamide
• CAS: 4653-12-7
• 化学式: C₈H₁₁NOS
• mdl: MFCD11643157
• 分子量: 169.247
• InChiKey: PIKMBAHDMDTNQE-UHFFFAOYSA-N

物化性质

• 熔点：
  82-83 °C
• 沸点：
  360.6±25.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  71.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-[2]thienyl-butyric acid amide 在 氢氧化钾 作用下， 生成 4-[2]thienyl-butyric acid-(4-bromo-phenacyl ester)
  参考文献：
  名称：

  The Willgerodt Reaction in the Heterocyclic Series. III. Temperature Studies with Thienyl Ketones

  摘要：

  DOI：

  10.1021/ja01124a061
• 作为产物：
  描述：

  4-(2-噻吩基)丁酰氯 在 ammonium hydroxide 作用下， 生成 4-[2]thienyl-butyric acid amide
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1953, p. 62,68, 713, 717

  摘要：

  DOI：

文献信息

• Cyanoamidine P2X7 antagonists for the treatment of pain
  申请人：Carroll A. William

  公开号：US20060025614A1

  公开（公告）日：2006-02-02

  Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R 1 -R 12 are as defined in the specification act as antagonists of the P2X 7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.

  新型氰胺基化合物的化学式(I)和(II)及其衍生物，其中R1-R12如规范中定义的作为P2X7受体的拮抗剂。这些化合物在治疗疼痛、炎症和神经退行性状态方面特别有用。
• [EN] OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION COMME AGENTS ANTIMYCOBACTERIENTS
  申请人：LUPIN LTD

  公开号：WO2004026848A1

  公开（公告）日：2004-04-01

  Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai. The compound and its pharmaceutically acceptable salts thereof act as antibacterial agents. Also disclosed is a method for inhibiting growth of mycobacterial cells a well as a method of treating mycobacterial conditions such as Mycobacterium tuberculoses, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai, comprising administering an antimycobacterially effective amount of the said compound and/or pharmaceutically acceptable salts thereof. There is also disclosed a process for the manufacture of the said compound or its pharmaceutically acceptable salts.

  新型化合物属于噁唑烷酮类，具有强效抗分枝杆菌特性，特别适用于治疗酸快速生长的微生物，如结核分枝杆菌、分枝杆菌内复合体、堪萨斯分枝杆菌和康萨分枝杆菌。该化合物及其药学上可接受的盐作为抗菌剂。还公开了一种抑制分枝杆菌细胞生长的方法，以及治疗结核分枝杆菌病、耐药性结核分枝杆菌、分枝杆菌内复合体、堪萨斯分枝杆菌和康萨分枝杆菌等分枝杆菌疾病的方法，包括给予所述化合物和/或其药学上可接受的盐的抗分枝杆菌有效量。还公开了一种制造所述化合物或其药学上可接受的盐的方法。
• [EN] BIARYL AMIDE OR UREA DERIVATIVES AS TRPV1 LIGANDS<br/>[FR] DÉRIVÉS DE BIARYL AMIDE OU D'URÉE EN TANT QUE LIGANDS DE TRPV1
  申请人：UNIV SIENA

  公开号：WO2015162216A1

  公开（公告）日：2015-10-29

  The present invention relates to high affinity compounds, able to bind the transient receptor potential cation channel, subfamily Vanilloid, type 1 or TRPV1. Being this receptor involved in pain processing and neurogenic inflammatory responses and being up-regulated during chronic pain conditions, the compounds of the invention find particular application in all medical conditions involving said receptors, in particular as agents for pain therapy and/or anti-inflammatory and/or cluster headache therapy and/or anti-oxidant and/or anti-cancer therapy. Moreover, the chemical structure of these compounds provides the opportunity of developing new radiotracers for Positron Emission Tomography (PET) imaging. These radiotracers are of great relevance for mapping TRPV1 receptors in (patho)physiological conditions.

  本发明涉及高亲和力化合物，能够结合瞬时受体电位阳离子通道，亚家族Vanilloid，类型1或TRPV1。由于这种受体参与疼痛处理和神经源性炎症反应，并且在慢性疼痛情况下上调，本发明的化合物在涉及该受体的所有医学状况中找到特定应用，特别是作为疼痛治疗和/或抗炎疗法和/或群集性头痛治疗和/或抗氧化剂和/或抗癌疗法的药物。此外，这些化合物的化学结构为开发新的正电子发射断层扫描（PET）成像的放射示踪剂提供了机会。这些放射示踪剂对于在（病理）生理条件下映射TRPV1受体具有重要意义。
• ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS
  申请人：MERCK PATENT GMBH

  公开号：US20150361037A1

  公开（公告）日：2015-12-17

  The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.

  本发明涉及公式（I）的化合物，特别是涉及至少一种公式I化合物构成的药物，用于治疗和/或预防在其中天冬氨酸蛋白酶D参与的生理和/或病理生理状况，特别是用于治疗和/或预防骨关节炎、创伤性软骨损伤、关节炎、疼痛、触痛或过敏性疼痛。
• Erythromycin derivatives
  申请人：Roussel Uclaf

  公开号：US05527780A1

  公开（公告）日：1996-06-18

  A compound selected from the group consisting of a compound of the formula ##STR1## wherein R is --(CH.sub.2).sub.n --Ar.sub.1 or --XAr.sub.2, n is an integer from 1 to 6, Ar.sub.1 and Ar.sub.2 are individually selected from the group consisting of a) carbocyclic aryl of up to 18 carbon atoms substituted by at least one member of the group consisting of free carboxy, alkoxy carbonyl and carboxyl salified with a pharmaceutically acceptable base, --OH, halogen, --NO.sub.2, --CN, ##STR2## and alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, N-alkyl, N-alkenyl and N-alkynyl of up to 12 carbon atoms optionally substituted with at least one halogen, R.sub.1 and R.sub.2 are individually hydrogen or alkyl of 1 to 12 carbon atoms, b) ##STR3## wherein R.sub.3 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, optionally substituted carbocyclic aryl, aryloxy and arylthio, optionally substituted heterocyclic aryl, aryloxy and arylthio containing at least one heteroatom with the optional substituents being those of carbocyclic aryl above, X is an alkyl of 1 to 6 carbon atoms interrupted by a member of the group consisting of --O--, --S--, --SO--, --SO.sub.2, --CO--, ##STR4## Z is hydrogen or acyl of an organic carboxylic acid of up to 18 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having antibiotic activity against gram positive and gram negative bacteria.

  从以下化合物组中选择的一种化合物，其中化合物的结构式为##STR1##其中R为--(CH.sub.2).sub.n --Ar.sub.1或--XAr.sub.2，n为1到6的整数，Ar.sub.1和Ar.sub.2分别从以下组中选择：a)由最多18个碳原子的碳环芳基组成，至少被该组中的自由羧基，烷氧羰基和经药用可接受碱盐化的羧基取代的，--OH，卤素，--NO.sub.2，--CN，##STR2##和烷基，环烷基，烯基，炔基，烷氧基，烯基氧基，炔基氧基，烷硫基，烯基硫基，炔基硫基，最多含有12个碳原子的N-烷基，N-烯基和N-炔基，可选地被至少一个卤素取代，R.sub.1和R.sub.2分别为氢或1到12个碳原子的烷基；b)##STR3##其中R.sub.3选择自1到12个碳原子的烷基，可选地取代的碳环芳基，芳氧基和芳硫基，可选地取代的含有至少一个杂原子的杂环芳基，芳氧基和芳硫基，其中可选的取代基为上述碳环芳基的取代基，X为由--O--，--S--，--SO--，--SO.sub.2，--CO--中的一种打断的1到6个碳原子的烷基，##STR4##Z为最多18个碳原子的有机羧酸酰基或其无毒的、药用可接受的酸盐，具有对革兰氏阳性和阴性细菌具有抗生素活性。